February 22, 2022
ICER has announced its intent to issue a final evidence report in this review without first holding a public hearing, a highly unusual decision.
February 17, 2022
Even after vowing to expand patients’ engagement in its process, the nation’s most active health technology assessment organization has shut them out.
October 15, 2021
ICER’s priorities differ from severe asthma patients’, and the economists’ approach could make it harder for patients to access the…
October 12, 2021
Just as asthma impacts people differently, existing treatment options serve some patients better than others.
July 9, 2021
The admonition to the Institute for Clinical and Economic Review’s Beacon Hill economists should be quite simple: “Stay in your lane.”
June 3, 2021
Alzheimer’s and dementia already afflict too many people, yet their prevalence is expected to more than double in the coming…
May 28, 2021
The Institute for Clinical and Economic Review claims that the first disease-modifying treatment for Alzheimer’s disease isn’t worth its cost.
May 11, 2021
The heartbreaking headline said it all: a new CAR-T personalized cancer treatment was found “effective, but too costly” by the economists at the Institute for Clinical and Economic Research.
April 30, 2021
An efficacious treatment that reduces the symptoms and risk factors associated with obstructive hypertrophic cardiomyopathy delivers great value to patients.…
April 30, 2021
Very few of the more than 5 million Americans, or their caregivers, who live with Alzheimer’s have ever heard of the Institute for Clinical and Economic Review.
